Structural Heart > TAVI Portfolio > ACURATE neo2 Aortic Valve System > Preserving Future Options

Today’s TAVI requires easy commissural alignment.


With TAVI treatment expanding to increasingly younger patient populations, the need for commissural alignment and preserving coronary access has become more critical.

 
 
 

Best-in-class commissural alignment demonstrated in COMALIGN.1

In the first study of patient-specific TAVI implantation techniques, ACURATE neo2 was the only valve to 100% avoid moderate/severe commissural misalignment.

COMALIGN Competitive Results Chart
 
View the full COMALIGN Study Results
 
Future Treatment Options Open

Align with Confidence

Watch the Case to learn more about commissural alignment with ACURATE neo2 with Federico De Marco and Matteo Casenghi from San Donato, Italy.

Angio image
  Watch Video  
 
 

Re-Access with confidence


Up to 75% of TAVI patients
have coronary artery disease2


0% coronary obstruction demonstrated
by ACURATE™ platform*, 2, 3

Future Treatment Options Open

Keeping Future Treatment Options Open

ACURATE neo2's unique design provides coronary clearance and preserves access where others may not.

Acurate neo 2
  Watch Video  
 
 
 

Treating today, ready for tomorrow.

ACURATE neo2™ product image
 

Extra-Wide Stabilization Arches

Stable deployment for future interventions
Extra-wide stabilization arches

Supra-annular leaflets free from stent frame

Valve leaflets are not encapsulated behind a stent frame, minimizing the risk of caging the aortic root
Supra-annular leaflets free from stent frame

Upper-crown caps native leaflets

 
 
 
 

The RE-ACCESS Study‡,2

Coronary Cannulation After TAVR

ACURATE neo: the only supra-annular valve platform demonstrating 100% successful coronary cannulation.

ACURATE neo valve platform

demonstrated

100%

successful coronary
cannulation
n=72

Evolut R/PRO
 

demonstrated

82%

successful coronary
cannulation
n=123

SAPIEN
 

demonstrated

99%

successful coronary
cannulation
n=96

 
 
 
Top